Abbott Has Selected Two Additional Cancer Targets From Celera Genomics For Further Development
Seven Celera Genomics Antigens Now in Research Pipeline with Partners
Celera Genomics Group, an Applera Corporation business, announced that Abbott has selected two Celera antigen targets for further investigation and potential therapeutic development. These are in addition to the two targets Abbott selected for advancement in April 2005 and the two targets announced earlier this month. Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Any of these antigens may be selected for therapeutic development at Abbott. Once this development is complete, Celera Genomics may elect to jointly fund clinical development and commercialization of any resulting therapeutic products and would share any financial returns resulting from commercialization, or alternately be paid milestones and royalties on successful therapies. Abbott has responsibility for the commercialization of jointly funded collaboration products. Celera Genomics retains certain diagnostic rights associated with selected targets.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous